Aurinia Pharmaceuticals Inc. (AUPH)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 5.10 |
| Open | 5.12 |
| Bid | 5.13 x 200 |
| Ask | 5.19 x 100 |
| Day's Range | 5.04 - 5.18 |
| 52 Week Range | 4.71 - 12.43 |
| Volume | |
| Avg. Volume | 2,160,108 |
| Market Cap | 737.978M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
ROCKVILLE, Md. & EDMONTON, Alberta, May 02, 2024--AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS
- Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
ROCKVILLE, Md. & EDMONTON, Alberta, May 01, 2024--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
- Business Wire
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
ROCKVILLE, Md. & EDMONTON, Alberta, April 30, 2024--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
© 2024 Yahoo. All rights reserved.